Skip to content

Search

Showing results for "lung disease preterm"

Novel end points for clinical trials in young children with cystic fibrosis

Cystic fibrosis (CF) lung disease commences early in the disease progression and is the most common cause of mortality.

Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry

Measurement of lung volumes across the life course is critical to the diagnosis and management of lung disease. The aim of the study was to use the G…

Arsenic and respiratory disease

Arsenic is the only environmental toxin that has been linked to both malignant and nonmalignant respiratory disease following ingestion, rather than…

Air trapping in early cystic fibrosis lung disease-Does CT tell the full story?

Mosaic attenuation on expiratory chest computed tomography (CT) is common in early life cystic fibrosis (CF) and often referred to as "air trapping"

Early life rhinovirus infection exacerbates house-dust-mite induced lung disease more severely in female mice

Early life rhinovirus infection influences the development of house-dust-mite induced lung disease in female, but not male mice

Oxidative stress and abnormal bioactive lipids in early cystic fibrosis lung disease

Several lipid biomarkers of early cystic fibrosis lung disease were identified, which point toward potential disease monitoring and therapeutic appro…

Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?

Clinical trials for the treatment of cystic fibrosis (CF) lung disease are important to test and optimise new therapeutic interventions.

The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial

Structural lung disease and neutrophil-dominated airway inflammation is present from 3 months of age in children diagnosed with cystic fibrosis after…

DEFEND CF: Biomarkers to define the treatment end-point for pulmonary exacerbations in cystic fibrosis

Sensitive and reliable tests are required to monitor lung disease severity in cystic fibrosis. A number of potential ... investigate how these tests…